Human GYG1 shRNA Lentivirus
Validated human Glycogenin-1 (GYG1) shRNA lentivirus: High-titer shRNA lentiviral particles specific for human Glycogenin-1 (GYG1). The shRNA has been validated to meet or exceed 70% GYG1 knockdown efficiency using a specific fluorescence-based method that is more rapid and reliable than qPCR. The shRNA lentivirus is ultra-purified and concentrated to high-titer by PEG precipitation and sucrose gradient centrifugation, and ideal for transducing difficult-to-transfect cells including thawed and/or primary cells.
- Same Cost For Custom Lentivirus – You can receive any combination of reporter (GFP/RFP/Luc/None) and selection marker (puromycin/blasticidin) for this product, without additional cost, by contacting us. To view our complete list of shRNA vectors, click here.
- Superior knockdown – LipExoGen Validated shRNA Lentiviruses are produced using the third generation system and feature novel, optimized shRNA vectors which express a 19-20 bp shRNA, fluorescent (GFP or RFP) or luminescent (luciferase) reporter, and drug-selection marker (puromycin or blasticidin). Taking advantage of a proprietary prediction algorithm developed in-house, validated shRNA constructs are capable of delivering 70% or more knockdown efficiency with less off-target effects compared to longer or mixed-sequence shRNA/siRNAs.
- Superior validation – All of our pre-made shRNA constructs are validated in-house using a specific fluorescence-based method that is more reliable than traditional qPCR. The validation process leverages bicistronic expression of the target mRNA and fluorescent reporter to confirm the efficacy of the shRNA. As knockdown validation can be readout using basic fluorescence microscopy, this low-cost, streamlined approach allows us to provide a superior-quality product at a price comparable or less than the average competitor.
- Superior accuracy – Polyclonal shRNA-transduced stable cells can be established within 10 days and used for downstream applications while preserving more properties of the parental cells. In this way, high-efficiency knockdown from our validated shRNA lentiviral particles can be advantageous over sgRNA CRISPR-Cas9 systems which select for single cell clones.
- Easily identify transduced cells – Validated shRNA constructs contain both fluorescent reporter and drug selection marker, allowing the flexibility to select transduced cells by puromycin/blasticidin or FACS sorting of GFP/RFP. Luciferase reporters are also available for detecting transduced cells in vitro or in vivo using luminescence-based techniques.
Figure 1. Knockdown validation for hGYG1-sh-GFP-Puro. HEK293FT cells were co-transfected with human GYG1-RFP bicistronic expression plasmid (red) and plasmids for the indicated shRNAs (GFP, green). After 24-36 hours, fluorescent images of the living cells were acquired by fluorescence microscopy. GFP represents transfection of the shRNA construct, whereas RFP indicates translation of the target mRNA. Higher knockdown efficiencies may be possible in stably-transfected cells. Sr-sh, scrambled shRNA.
If you require a modification to one of our products (for example, change in reporter or other vector component), please request a custom order. We provide a variety of fast and efficient services for the production of high-quality, custom lentiviral particles on demand, usually for the same or comparable price as the listed item.
Or, send us your cells and we will establish a stable shRNA cell line for you using this product. Learn more.
The cDNA lentivirus corresponding to this product is also available upon request, comparable price.
I want to:
|Gene IDs||HGNC:HGNC:4699 Ensembl:ENSG00000163754 MIM:603942|
|Entrez Gene Summary||“This gene encodes a member of the glycogenin family. Glycogenin is a glycosyltransferase that catalyzes the formation of a short glucose polymer from uridine diphosphate glucose in an autoglucosylation reaction. This reaction is followed by elongation and branching of the polymer, catalyzed by glycogen synthase and branching enzyme, to form glycogen. This gene is expressed in muscle and other tissues. Mutations in this gene result in glycogen storage disease XV. This gene has pseudogenes on chromosomes 1, 8 and 13 respectively. Alternatively spliced transcript variants encoding different isoforms have been identified.[provided by RefSeq, Sep 2010]”|